TOP1
ENSG00000198900
Target class
Enzyme
Chromosome
20
Approved drugs
4
Clinical candidates (approved and in development)
24
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 24
- Chemical probe available
- Yes
- Target name
- TOP1
- Gene name
- DNA topoisomerase I
- Gene symbol
- TOP1
- Protein name
- DNA topoisomerase 1 (EC 5.6.2.1) (DNA topoisomerase I)
- Gene biotype
- Protein coding
- Gene family
- Topoisomerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 133.84
- Tissue specificity (Gini)
- 0.267
- Tissue specificity (tau)
- 0.702
- KEGG gene identifiers
- hsa:7150
- Reactome pathways
- R-HSA-4615885
- Protein interaction confidence
- 0.804327
- Protein interaction partners
- 55
- End position
- 41124487
- Start position
- 41028822
- Chromosome
- 20
- Strand
- Forward
- Nucleus, nucleolus . Nucleus, nucleoplasm . Note=Diffuse nuclear localization with some enrichment in nucleoli. On CPT treatment, cleared from nucleoli into nucleoplasm. Sumoylated forms found in both nucleoplasm and nucleoli.
- Nucleoli fibrillar center
- Nucleoplasm
Publication evidence
- PubMed 12149243
- Tissue specificity (tau)
- 0.702232
- Expression inequality (Gini)
- 0.267034
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 133.84
- Cells - Cultured fibroblasts
- 95.96
- Lung
- 79.82
- Thyroid
- 67.22
- Brain - Cerebellar Hemisphere
- 60.28
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes133.84
- Cells - Cultured fibroblasts95.96
- Lung79.82
- Thyroid67.22
- Brain - Cerebellar Hemisphere60.28
- Vagina59
- Spleen58.93
- Esophagus - Mucosa56.86
- Fallopian Tube56.23
- Cervix - Endocervix56.09
- Ovary54.83
- Adipose - Visceral (Omentum)54.35
- Small Intestine - Terminal Ileum54.08
- Uterus54.06
- Cervix - Ectocervix53.91
- Brain - Cerebellum49.96
- Skin - Sun Exposed (Lower leg)48.36
- Breast - Mammary Tissue47.15
- Pituitary46.41
- Skin - Not Sun Exposed (Suprapubic)46.23
- Adrenal Gland45.93
- Prostate45.69
- Bladder44.13
- Colon - Transverse43.78
- Nerve - Tibial43.54
And 29 more, listed on the interactive page.
- GO:0006265
- GO:0006338
- GO:0007623
- GO:0009410
- GO:0032922
- GO:0000228
- GO:0001650
- GO:0005634
- GO:0005654
- GO:0005730
- GO:0032993
- GO:0036464
- GO:0000978
- GO:0003677
- GO:0003682
- GO:0003690
- GO:0003697
- GO:0003723
- GO:0003917
- GO:0004674
- GO:0005515
- GO:0005524
- GO:0008301
- GO:0019904
- GO:0097100
- GO:0140693
Related records
Trials (2,285)
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- 26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
- 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
- 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
- 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
- 9-ING-41 in Patients With Advanced Cancers
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
- A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
- A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
- A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.
Drugs (26)
- 7-ethyl-10-hydroxycamptothecin DNA topoisomerase I inhibitor
- 9-aminocamptothecin DNA topoisomerase I inhibitor
- Afeletecan DNA topoisomerase I stabiliser
- AR-67 DNA topoisomerase I inhibitor
- Becatecarin DNA topoisomerase I inhibitor
- Belotecan DNA topoisomerase I inhibitor
- Camptothecin-20-O-propionate DNA topoisomerase I inhibitor
- Datopotamab deruxtecan DNA topoisomerase I inhibitor
- Diflomotecan DNA topoisomerase I inhibitor
- Edotecarin DNA topoisomerase I inhibitor
- Etirinotecan pegol DNA topoisomerase I inhibitor
- Exatecan DNA topoisomerase I inhibitor
- Gimatecan DNA topoisomerase I inhibitor
- Irinotecan DNA topoisomerase I inhibitor
- Irinotecan hydrochloride DNA topoisomerase I inhibitor
- Irinotecan sucrosofate DNA topoisomerase I inhibitor
- Karenitecin DNA topoisomerase I inhibitor
- Labetuzumab govitecan DNA topoisomerase 1 inhibitor
- Mureletecan DNA topoisomerase I inhibitor
- Patritumab deruxtecan DNA topoisomerase I inhibitor